A micrograph showing inflammatory responses in the cortex of the new model mouse. Alzheimer's disease patients and mouse ...

A new study has found important clues about the roles age, sex, hormonal changes and genetics play in how certain biomarkers ...

A new study has found important clues about the roles age, sex, hormonal changes and genetics play in how certain biomarkers ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Researchers have dosed the first participant in a clinical trial of an investigational medicine designed to lower the amount ...

The first approved drug in the EU to treat patients in the early stages of Alzheimer’s disease has been given the go ahead ...

Explore 6 hopeful Alzheimer’s treatment paths, from innovative therapies to promising research, offering new possibilities ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

Lifeforce, the world's leading longevity medicine program, has introduced the Lifeforce Brain Protection Program, a first-of-its-kind solution for people wanting to proactively take control of their ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...